Platinum Drug Resistance in Ovarian Cancer Models
Author Information
Author(s): M. Jones, J. Siracky, L.R. Kelland, K.R. Harrap
Primary Institution: The Institute of Cancer Research
Hypothesis
Can human ovarian carcinoma xenografts develop resistance to platinum-based drugs?
Conclusion
The study established that resistance to platinum drugs can be generated in human ovarian carcinoma xenografts, with observed cross-resistance patterns.
Supporting Evidence
- Resistance was generated to cisplatin, carboplatin, iproplatin, and tetraplatin.
- Four tumors showed complete cross-resistance to the remaining platinum agents.
- One line retained sensitivity to cisplatin and carboplatin despite resistance to iproplatin.
Takeaway
Researchers found that some ovarian cancer tumors can become resistant to chemotherapy drugs, making them harder to treat. They created models to study this resistance.
Methodology
The study used six human ovarian carcinoma xenografts to establish resistance to various platinum drugs through in vivo and in vitro treatments.
Limitations
The study primarily focused on a limited number of tumor lines and may not represent all ovarian cancers.
Participant Demographics
Tumor lines derived from previously untreated and treated patients.
Want to read the original?
Access the complete publication on the publisher's website